Product Description
Eltrombopag, an orally administered, small-molecule non-peptide thrombopoietin receptor agonist, selectively binds to the transmembrane domain of the thrombopoietin receptor on the surface of platelets, megakaryocytes and megakaryocyte precursor cells. The drug acts via the Janus Kinase/Signal Transducer and Activator of Transcription (JAK/STAT) pathway to activate megakaryocyte proliferation and differentiation in bone marrow progenitor cells, similar to those observed with endogenous thrombopoietin. (Sourced from: https://pubmed.ncbi.nlm.nih.gov/19368418/)
Mechanisms of Action: TPO Inhibitor
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: Hepatitis | Hepatitis, Chronic | Anemia | Anemia, Aplastic | Thrombocytopenia | Purpura, Thrombocytopenic, Idiopathic | Hepatitis C | Hepatitis C, Chronic | Injuries/wounds Unspecified
Known Adverse Events: Headache | Anemia | Diarrhea
Company: GlaxoSmithKline
Company Location: BRENTFORD MIDDLESEX X0 TW8 9GS
Company CEO: Emma Walmsley
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: Austria, Brazil, Chile, China, Czech Republic, France, Germany, Greece, Hong Kong, Italy, Japan, Korea, Mexico, Oman, Portugal, Russia, Spain, Switzerland, Taiwan, Thailand, Turkey, United Kingdom, United States
Active Clinical Trial Count: 22
Highest Development Phases
Phase 3: Anemia, Aplastic|Pancytopenia
Phase 2: Acute Myeloid Leukemia|Anemia, Refractory|Chronic Lymphoid Leukemia|Communicable Diseases|Graft vs Host Disease|Lymphocytic Chronic B-Cell Leukemia|Lymphoma|Myelodysplastic Syndrome|Preleukemia|Purpura, Thrombocytopenic, Idiopathic|Stem Cell Transplant|Thrombocytopenia
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| 2023-505788-35-00 | P2 |
Not yet recruiting |
Thrombocytopenia|Purpura, Thrombocytopenic, Idiopathic |
2027-12-01 |
|
| CETB115L11201 | P2 |
Recruiting |
Preleukemia|Myelodysplastic Syndrome |
2026-01-15 |
24% |
| 2015-003166-91 | P2 |
Unknown status |
Anemia, Refractory|Anemia, Aplastic |
2025-11-22 |
|
| EPBSCH | P2 |
Recruiting |
Lymphoma|Stem Cell Transplant |
2025-03-31 |